Opaganib
Prostate Cancer
Key Facts
About RedHill Biopharma
RedHill Biopharma is a publicly traded, Israel-based company dedicated to developing and commercializing novel, primarily oral, small-molecule drugs for significant unmet medical needs. Its strategy integrates in-house R&D with strategic acquisitions to build a portfolio focused on GI diseases, infectious diseases, and oncology. A key achievement is establishing a late-stage pipeline of host-directed oral antivirals designed as broad-spectrum, mutation-resistant medical countermeasures suitable for government stockpiling.
View full company profileAbout RedHill Biopharma
RedHill Biopharma is a publicly traded, Israel-based company dedicated to developing and commercializing novel, primarily oral, small-molecule drugs for significant unmet medical needs. Its strategy integrates in-house R&D with strategic acquisitions to build a portfolio focused on GI diseases, infectious diseases, and oncology. A key achievement is establishing a late-stage pipeline of host-directed oral antivirals designed as broad-spectrum, mutation-resistant medical countermeasures suitable for government stockpiling.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| MagSense™ PSMA Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| Leronlimab | CytoDyn | Preclinical |
| CROES Registry | AngioDynamics | Post-Market Registry |
| Cannabics® PRST-33 | CNBX Pharmaceuticals | Discovery |
| HDP-103 | Heidelberg Pharma | Preclinical |
| ENV105 | Kairos Pharma | Phase 2 |
| AI for Prostate Cancer | Invenio Imaging | Research |
| Mitomic™ Test for Prostate Cancer | MDNA Life Sciences | Development/Validation |